Session » RA – Treatments Poster I: Novel Treatments

Date: Sunday, November 10, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 542

‘BENEFIT’ Pan-European Observational Study to Evaluate the Real-world Effectiveness of SB4 Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis or Axial Spondyloarthritis: A Switch Success Story

9:00AM-11:00AM: Abstract Number: 511

A Comparative Analysis of Upadacitinib Monotherapy and Upadacitinib Combination Therapy for the Treatment of Rheumatoid Arthritis from Two Phase 3 Trials

9:00AM-11:00AM: Abstract Number: 524

A Comparison of Upadacitinib Plus Methotrexate and Upadacitinib Plus Other CsDMARDs in Patients with Rheumatoid Arthritis: An Analysis of Two Phase 3 Studies

9:00AM-11:00AM: Abstract Number: 532

A Phase 2 Study of E6011, an Anti-Fractalkine Monoclonal Antibody, ㏌ Patients with Rheumatoid Arthritis Inadequately Responding to Biologics

9:00AM-11:00AM: Abstract Number: 503

A Pilot Phase 1, Randomized, Double-blind, Two-arm, Parallel Group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P17 and Humira in Healthy Male Subjects

9:00AM-11:00AM: Abstract Number: 514

A Pooled Analysis of 1-year Clinical Outcomes Among 6-month Responders and Non-responders from Three Randomized Controlled Studies of TNF Inhibitor Biosimilars in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 539

A Randomized Double-Blind Study Comparing Pharmacokinetics (PK) and Pharmacodynamics (PD) of ABP 798 with Rituximab in Subjects with Moderate to Severe RA

9:00AM-11:00AM: Abstract Number: 517

A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs

9:00AM-11:00AM: Abstract Number: 504

A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 528

Assessment of Bone and Cartilage Turnover Markers Following Treatment with Repository Corticotropin Injection in Patients with Persistently Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 546

Change in Rheumatoid Arthritis (RA)-Related Autoantibody Profile and Risk of Disease Flare After Withdrawal of Therapy in Patients with Early RA Treated with Abatacept and MTX

9:00AM-11:00AM: Abstract Number: 529

Characterization of Remission in Patients with Rheumatoid Arthritis Treated with Upadacitinib or Comparators

9:00AM-11:00AM: Abstract Number: 515

Clinical Responses in Patients with Inadequate Response to bDMARDs upon Treatment with Upadacitinib

9:00AM-11:00AM: Abstract Number: 540

Comparing Real-world Retention Rates in a Matched Cohort of Rheumatoid Arthritis Patients Who Either Remained on the Etanercept Originator or Switched to a Biosimilar

9:00AM-11:00AM: Abstract Number: 534

CXCL13 Serum Levels and Circulating Follicular Helper T-Cells Decrease After Co-stimulation Blockade with Abatacept in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 543

Cytokine Signaling Pathways Inhibited by Different Biologics in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 521

Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 548

Efficacy and Safety of a Novel Subcutaneous Formulation of CT-P13 over the 1-year Treatment Period and After Switching from Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis: Results from Part 2 of Phase I/III Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 506

Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results

9:00AM-11:00AM: Abstract Number: 531

Efficacy and Safety of Gonadotropin-Releasing Hormone Antagonism in Severe Biologic Refractory Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 512

Efficacy and Safety of Upadacitinib Monotherapy in MTX-naïve Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY

9:00AM-11:00AM: Abstract Number: 520

Efficacy and Safety Results from a Phase 3 Study of Biosimilar Candidate ABP 710 in Subjects with Moderate to Severe RA

9:00AM-11:00AM: Abstract Number: 537

Efficacy and Safety Results from a Randomized Double-Blind Study That Compared the Proposed Biosimilar ABP 798 with Rituximab in Subjects with Moderate to Severe RA

9:00AM-11:00AM: Abstract Number: 519

Efficacy of Biosimilar Candidate ABP 710 in a Phase 3 Study in Subjects with Moderate to Severe RA: Additional Analysis Focusing on the ACR Individual Components

9:00AM-11:00AM: Abstract Number: 553

Etanercept Biosimilar GP 2015 (Erelzi®) in Rheumatic Diseases: Interim Analysis of Real-World Data from COMPACT: A Multicentric, Prospective, Observational Cohort Study

9:00AM-11:00AM: Abstract Number: 554

Evidence to Guide Glucocorticoid Tapering Is Lacking in RA

9:00AM-11:00AM: Abstract Number: 535

Exploratory Analysis of a Phase 2b Study Confirms Substantial Pain Improvement with Anti-GM-CSF Monoclonal Antibody Otilimab (GSK3196165) in Patients (Pts) with Active RA

9:00AM-11:00AM: Abstract Number: 525

Factors Associated with Persistent Drug-free Remission in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 526

Factors Influencing Discontinuation in Long-term RA Treatment

9:00AM-11:00AM: Abstract Number: 516

Impact of Baseline Demographics and Disease Activity on Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib

9:00AM-11:00AM: Abstract Number: 533

Impact of Formulary Change on TNFi Treatment Patterns and Healthcare Utilization Costs in RA Patients

9:00AM-11:00AM: Abstract Number: 552

In the Real World Clinical Setting Etanercept Biosimilar SB4(BENEPAIL®) Demonstrates Equivalent Safety and Effectiveness in Biological Naïve as Well as with ENBREL® Pretreated RA,SPA, and PSA Patients

9:00AM-11:00AM: Abstract Number: 507

Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan

9:00AM-11:00AM: Abstract Number: 547

Inhibition of Structural Joint Damage with Upadacitinib as Monotherapy or in Combination with Methotrexate in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 538

Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks

9:00AM-11:00AM: Abstract Number: 508

Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan

9:00AM-11:00AM: Abstract Number: 505

Low-grade Total Rheumatoid Arthritis MRI Scoring System Can Predict Successful Half-dose Reduction of MTX in Patients with RA in Clinical Remission

9:00AM-11:00AM: Abstract Number: 545

Molecular Analysis of the Mode of Action of Upadacitinib in Rheumatoid Arthritis Patients: Whole Blood RNA Expression Data from the SELECT-NEXT Study

9:00AM-11:00AM: Abstract Number: 541

Multicenter, Evaluator-blinded, Randomized, Non-inferiority Study, to Assess the Efficacy, Safety and Immunogenicity of Etanercept Biosimilar (EtaBS) vs. Reference Etanercept (EtaRef) in Combination with Methotrexate for the Treatment of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 536

PERFUSE: A French Prospective/Retrospective Non-interventional Cohort Study of Infliximab-naïve and Transitioned Patients Receiving Infliximab Biosimilar SB2; An Interim Analysis

9:00AM-11:00AM: Abstract Number: 530

Phase I Evaluation of the PDE4 Inhibitor LY2775240: Head to Head Comparison with Apremilast Using an Ex Vivo Pharmacodynamic Assay

9:00AM-11:00AM: Abstract Number: 550

Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study

9:00AM-11:00AM: Abstract Number: 527

Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks

9:00AM-11:00AM: Abstract Number: 509

Safety Profile of Upadacitinib in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program

9:00AM-11:00AM: Abstract Number: 523

The Impact of Upadacitinib versus Methotrexate or Adalimumab on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 544

Tolerance, Survival, and Adherence to Methotrexate Treatment in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 510

Treatment with Upadacitinib Is Associated with Improvements in Reverse Cholesterol Transport in Patients with Rheumatoid Arthritis: Correlation with Changes in Inflammation and HDL Levels

9:00AM-11:00AM: Abstract Number: 522

Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 513

Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 Weeks

9:00AM-11:00AM: Abstract Number: 518

Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks

9:00AM-11:00AM: Abstract Number: 551

Upadacitinib Treatment and the Routine Assessment of Patient Index Data 3 (RAPID3) Among Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 549

US Rheumatologists’ Beliefs and Knowledge About Biosimilars – an Ongoing Survey

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].